After nearly a ten-year period, the Food and Drug Administration (FDA) has at last finalized the Informed Consent guidance document (Final Guidance). This marks a critical juncture in the drafting and reviewing process that began in 2014 with the Informed Consent Information Sheet guidance document (Draft Guidance). The completion of the Final Guidance supersedes the FDA’s 1998 document, titled “A Guide to Informed Consent”. The FDA’s move comes within the larger context of ongoing efforts to modernize and harmonize human subject protection regulations and policies.
The FDA’s Final Guidance represents a commitment to clarity and ethics in research involving human subjects. The document provides a comprehensive framework for understanding how informed consent should be obtained and maintained in compliance with FDA policies and regulations.
Initiatives like these by the FDA demonstrate the agency’s commitment to updating and optimizing its framework around ethical and legal boundaries in research involving human subjects. Such measures work towards increasing the confidence of both research entities and the public in the agency’s regulatory decisions.
For more granular details regarding this development, you can read the full article
here.